Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních věcí,
xxxxxx se xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních věcí x. 58/2007 Xx. x. x. x x. 46/2008 Sb. x. x. x xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx x. 97/2012 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, xx xxx 12. listopadu 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Mezinárodní xxxxxxxx Mezinárodní úmluvy xxxxx dopingu xx xxxxxx1).
X novým xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky.
Xxxx xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x souladu x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2013 x xxxxx xxxx xxxxxxxxx v platnost x pro Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2012 a xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X x její překlad xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx xxx 19. října 2005 x Paříži xxxx vyhlášena xxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
XXXXXXX X
XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx kodexu všechny Xxxxxxxx xxxxx budou xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx S1, X2, S4.4, X4.5 x X6(x) x Xxxxxxxxxx metod X1, X2 x M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(XXX XXXXXXX X XXXX XXXXXX)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Jakákoliv xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx sekcích Seznamu x není aktuálně xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxx xxxx po ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), je xxxxxxxx stále.
X1. XXXXXXXXXX LÁTKY
Anabolické xxxxx jsou zakázány.
1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; boldion (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-hydroxy-17α-methylestra-4,9,11-trien-3-on); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx látky x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x jejich xxxxxxxxxx x xxxxxxx, xxx ne x xxxxxxxx xxxxx na xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (androst-5-en-3,17-dion)
|
|
5α-androstan-3α,17β-diol
|
|
|
5α-androstan-3β,17α-diol
|
epi-dihydrotestosteron
|
|
5α-androstan-3β,17β-diol
|
epitestosteron
|
|
androst-4-en-3α,17α-diol
|
3α-hydroxy-5αandrostan-17-on
|
|
androst-4-en-3α,17β-diol
|
3β-hydroxy-5αandrostan-17-on
|
|
androst-5-en-3β,17α-diol
|
7α-hydroxy-DHEA
|
|
androst-5-en-3α,17α-diol
|
7β-hydroxy-DHEA
|
|
androst-5-en-3α,17β-dioI
|
7-keto-DHEA
|
|
androst-5-en-3β,17α-diol
|
19-norandrosteron
|
|
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Ostatní xxxxxxxxxx xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x omezením xxxxx xx xx.
| &xxxx;
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx vztahuje x xxxxx, xxxxxx xxxx xxxx normálně schopno xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx přirozeně.
|
X2. PEPTIDOVÉ HORMONY, XXXXXXX XXXXXXX A XXXXXXXX XXXXX
Následující xxxxx a xxxxxx xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx erytropoesu (např. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (CERA), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (CG) x Xxxxxxxxxxxx hormon (XX) x mužů;
3. Xxxxxxxxxxxxxx;
4. Růstový xxxxxx (GH), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx růstové xxxxxxx (XXX), růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx degradaci xxxxxxxx xxxxx, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, regenerativní xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx;
x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx kromě xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 xxxxx), xxxxxxxxxxx (maximálně 36 xxxxxxxxxx xx 24 xxxxx) a salmeterolu xxxxx jsou xxxxxx x xxxxxxxx v xxxxxxx x xxxxxxxxxxx xxxxxxxx režimem výrobce.
Xxxxxxxxxx xxxxxxxxxxx v xxxx x xxxxxxxxxxx xxxxx než 1000 xx/xx a xxxxxxxxxx xxxxxxxxxxx v xxxx x koncentraci xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické použití, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxx xxxxxxxx terapeutické xxxxxxxxx xxxxx nižší xxx xxxx xxxxxxx xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX MODULÁTORY
Xxxxxxxx xx následující:
1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, testolacton, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxx xx x omezením xxxxx na xx.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx x omezením xxxxx na xx.
4. Xxxxx modifikující xxxxxx myostatinu včetně xxxxxxxxxx myostatinu, xxx xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx modulátory:
x) Insuliny;
b) Xxxxxxxx delta aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (PPARδ) xxxxxxxx/ (xxxx. GW 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x xxxxxxxxxxx x XXXX delta /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. DIURETIKA X XXXXXXX XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Xxxxxxxx:
Xxxxxxxxx, xxxxxxxxxxxx, plasmaexpandery (xxxx. glycerol, xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx pro xxxxx anestézi není xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, xxxxxxxx etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx s xxxxxxxx chemickou strukturou xxxx podobnými biologickými xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx a lokálního xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které nejsou xxxxxxxx).
Pro xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) jakéhokoliv xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx výjimky xx xxxx látku navíc x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.
XXXXXXXX XXXXXX
M1. MANIPULACE X KRVÍ X XXXXXXXX KOMPONENTAMI
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx do xxxxxxxxx systému.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx produkty (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx a efaproxiral (XXX13), ale ne x omezením xxxxx xx xx. Suplementace xxxxxxxx zakázána xxxx.
3. Xxxxxxxxx forma xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx xxxx s xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX MANIPULACE
Zakázané xx následující:
1. Xxxxxxxxx, xxxx xxxxx x podvod, za xxxxxx porušit xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx xxxxxx (např. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx na ně.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
Z xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx zakázáno xxxxxxxxxxx:
1. Xxxxxxxx nukleových xxxxxxx nebo xxxxxx xxxxxxxx;
2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X XXXXXX XXXXXXXX XXX XXXXXXX
|
Xxxxx xxxxxxxxx X0 xx X5 x X1 xx X3 xxxxxxxxx výše xxxx Xxx Xxxxxxx zakázané x xxxxxxxxxxx skupiny:
XXXXXXXX XXXXX
X6. XXXXXXXXXXX
Xxxxxxx xxxxxxxxxxx xxxxxx všech jejich xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- x x-) xxxx zakázaná, x xxxxxxxx xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Adrafinil, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, dimethylamfetamin, xxxxxxxxxxxxxx, famprofazon, fendimetrazin, xxxxxxxxx, fenfluramin, fenkamin, xxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, xxxxxx, kropropamid, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, mezokarb, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx.
Stimulancium, xxxxx xxxx xxxxxxxx xxxxxxx x tomto xxxxxxxx, xx Specifickou látkou.
(x) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, fenkamfamin, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (dimetylpentylamin), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****selegilin, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx xxxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.
** Xxxxxxx xxxxxx xxxxxxxxxx (např. nosní, xxxx xxxxxxxx) xxxx xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.
*** Xxxxx xx xxxxxxxx xxxxx při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx moči.
**** Xxxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx než 10 mikrogramů v 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx jeho xxxxxxxxxxx x moči xx xxxxx xxx 150 mikrogramů na xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, dextromoramid, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
S8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, konopí x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Spice" /XXX018, JWH073/ x XX-210) xxxx xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx aplikací xxxx xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX XXXXXXXX
|
X1. XXXXXXX
Xxxxxxx (xxxxxx) xx xxxxxxxx pouze Při Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx dechovou xxxxxxxx a/nebo xxxxxxxx xxxx. Xxxxxxx xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (hematologická hodnota) xx 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Xxxxxxx xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Xxxxxxxxxxx sport (XXX)
∙ Vodní xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, beta-blokátory xxxx xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (FIA)
∙ Xxxxxxxx (všechny xxxxxxxxxx) (XXXX)
∙ Xxxx (IGF)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Mimo xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx xxxxxx a xxxxxxxxxxx lyžování-skoky x X-xxxxx,x xxxxxxxxx U-rampa x "big xxx"
∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (XXX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx látky:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, bisoprolol, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, levobunolol, xxxxxxxxxxxx, xxxxxxxxxx, nadolol, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. xxxxx účinnosti xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. x. x. xxx zrušen xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se jich xxxxxx derogační xxxxx xxxxx uvedeného právního xxxxxxxx.